Niterra Invests in Biolinq
We’re excited to share that Niterra’s venture capital fund, alongside Alpha Wave Ventures and other investors, has backed Biolinq in its series C funding round. Biolinq, based in California, is pioneering wearable biosensor technology for metabolic health. Their wearable patch assesses glucose levels and activity without needles or bleeding. Biolinq raised a total of $58 million in funding and aims to conduct clinical trials for their glucose sensor and seek FDA approval. It's a step towards simpler solutions for better metabolic health.
続きを読む